Feng Yan

Feng Yan


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2023 in Journal of Affective Disorders
Verified
Journal Article
Closed access
YDYang Du
Yang Du
JYJie Yu
Jie Yu
MLManhua Liu
Manhua Liu
QQQi Qiu
Qi Qiu
YFYuan Fang
Yuan Fang
XLXia Li
Xia Li

29 October 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
CHChun Huang
Chun Huang
YFYuan Fang
Yuan Fang
FYFeng Yan
Feng Yan
TWTao Wang
Tao Wang
CDCai Dong-Bin
Cai Dong-Bin
JWJianjun Wang
Jianjun Wang
Introduction Late-life depression (LLD) is a global public health issue, often accompanied by cognitive impairments that can exacerbate the severity of depression and impair social functioning. Despite being a well-established treatment for LLD, the suitability of problem-solving therapy (PST) for individuals with LLD and varying degrees of cognitive impairments warrants further investigation. This paper presents the protocol for a systematic review and meta-analysis of randomised controlled trials (RCTs) aimed at evaluating the effectiveness and acceptability of PST for this specific demographic. Methods/analysis Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we will conduct a systematic review to synthesise existing research on PST for individuals in this demographic. We will comprehensively search multiple databases and sources, including PubMed, EMBASE, the Cochrane Database and APA PsycNET from inception to October 2023, without language, publication year or type restrictions. Relevant studies will be manually screened from the references. Only RCTs involving PST for LLD will be included. The primary efficacy outcome will be the standardised mean difference in total scores on continuous depression severity scales across different comparison arms. Data extraction will be conducted independently by two reviewers (CH and J-JW), and methodological rigour will be assessed using the Cochrane Risk of Bias assessment tool. Subgroup and sensitivity analyses will be performed to investigate the impact of concomitant cognitive impairments and to evaluate the robustness of the findings. Ethics and dissemination The meta-analysis project is expected to be ethically unproblematic and does not require approval from a research ethics committee. The results of this study will be shared through articles in scholarly peer-reviewed journals and presentations in various formats, both print and digital. PROSPERO registration number CRD42023473782